BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 19495749)

  • 1. Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data.
    Aalto S; Scheinin NM; Kemppainen NM; Någren K; Kailajärvi M; Leinonen M; Scheinin M; Rinne JO
    Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1651-60. PubMed ID: 19495749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.
    Kemppainen NM; Aalto S; Wilson IA; Någren K; Helin S; Brück A; Oikonen V; Kailajärvi M; Scheinin M; Viitanen M; Parkkola R; Rinne JO
    Neurology; 2006 Nov; 67(9):1575-80. PubMed ID: 16971697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.
    Tolboom N; Yaqub M; Boellaard R; Luurtsema G; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
    Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1629-38. PubMed ID: 19384547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.
    Grimmer T; Riemenschneider M; Förstl H; Henriksen G; Klunk WE; Mathis CA; Shiga T; Wester HJ; Kurz A; Drzezga A
    Biol Psychiatry; 2009 Jun; 65(11):927-34. PubMed ID: 19268916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease.
    Mikhno A; Devanand D; Pelton G; Cuasay K; Gunn R; Upton N; Lai RY; Libri V; Mann JJ; Parsey RV
    J Nucl Med; 2008 Aug; 49(8):1262-9. PubMed ID: 18632806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility.
    Edison P; Brooks DJ; Turkheimer FE; Archer HA; Hinz R
    Neuroimage; 2009 Nov; 48(2):329-38. PubMed ID: 19591948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?
    Edison P; Hinz R; Ramlackhansingh A; Thomas J; Gelosa G; Archer HA; Turkheimer FE; Brooks DJ
    Neuroimage; 2012 Apr; 60(3):1716-23. PubMed ID: 22306804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load.
    Alkalay A; Rabinovici GD; Zimmerman G; Agarwal N; Kaufer D; Miller BL; Jagust WJ; Soreq H
    Curr Alzheimer Res; 2013 Jan; 10(1):48-56. PubMed ID: 23157337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.
    Zhou Y; Resnick SM; Ye W; Fan H; Holt DP; Klunk WE; Mathis CA; Dannals R; Wong DF
    Neuroimage; 2007 Jun; 36(2):298-312. PubMed ID: 17449282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo mapping of amyloid toxicity in Alzheimer disease.
    Frisoni GB; Lorenzi M; Caroli A; Kemppainen N; Någren K; Rinne JO
    Neurology; 2009 Apr; 72(17):1504-11. PubMed ID: 19398705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
    Kemppainen NM; Aalto S; Wilson IA; Någren K; Helin S; Brück A; Oikonen V; Kailajärvi M; Scheinin M; Viitanen M; Parkkola R; Rinne JO
    Neurology; 2007 May; 68(19):1603-6. PubMed ID: 17485647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease.
    Koivunen J; Verkkoniemi A; Aalto S; Paetau A; Ahonen JP; Viitanen M; Någren K; Rokka J; Haaparanta M; Kalimo H; Rinne JO
    Brain; 2008 Jul; 131(Pt 7):1845-53. PubMed ID: 18583368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
    Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
    J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.
    Scheinin NM; Aalto S; Koikkalainen J; Lötjönen J; Karrasch M; Kemppainen N; Viitanen M; Någren K; Helin S; Scheinin M; Rinne JO
    Neurology; 2009 Oct; 73(15):1186-92. PubMed ID: 19726751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.
    Lopresti BJ; Klunk WE; Mathis CA; Hoge JA; Ziolko SK; Lu X; Meltzer CC; Schimmel K; Tsopelas ND; DeKosky ST; Price JC
    J Nucl Med; 2005 Dec; 46(12):1959-72. PubMed ID: 16330558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET.
    Rosario BL; Weissfeld LA; Laymon CM; Mathis CA; Klunk WE; Berginc MD; James JA; Hoge JA; Price JC
    Neuroimage; 2011 Apr; 55(3):933-41. PubMed ID: 21195782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
    Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K
    Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.